Summary

  • Copart agreed to pay $10.50 in cash for each ACV share, an implied equity value of about $1.9 billion and a 45% premium to ACV’s unaffected 10 August close. The offer has no financing condition, and Copart says existing cash will fund it.
  • The transaction still requires more than 50% of ACV’s outstanding stock to be tendered. Support agreements cover only about 4.1%; once the threshold and other conditions are met, Section 251(h) permits the back-end merger without another shareholder vote.
  • Copart must use reasonable best efforts to address competition objections, including through divestitures, licences, ended relationships, operating limits or restructuring. If specified antitrust conditions remain unresolved, the initial one-year End Date can extend by 180 days.
  • A specified regulatory failure can require Copart to pay ACV $115.3 million, twice the $57.7 million fee associated with specified ACV exits. The asymmetry prices different risks; it does not predict that regulators will intervene or guarantee that either fee becomes payable.

The easiest cheque in Copart’s proposed acquisition of ACV may be the purchase price. The harder payment is a commitment to carry competition risk after funding has stopped being an excuse.

On 10 September, Copart agreed to launch a cash tender offer for all ACV shares at $10.50 each. The companies put the implied equity value at approximately $1.9 billion and the premium at 45% to ACV’s unaffected closing price on 10 August, the last session before published reports of a possible transaction. Against the 30-day volume-weighted average through 9 September, the stated premium is 41%.

Those numbers describe what holders receive if the transaction closes. They do not describe what Copart must do to get there. The filed merger agreement removes one familiar escape route: neither debt financing nor an alternative financing is an offer or merger condition. Copart reaffirms that it must complete the transaction independently of whether financing is available, subject to the other conditions.

That is credible on the last reported balance sheet. At 30 April, Copart had $3.354 billion of cash, cash equivalents and restricted cash and another $845.6 million in held-to-maturity securities. Its transaction presentation says existing cash will fully fund the deal. The snapshot is not a closing certificate—cash moves, restricted cash is not all freely spendable and the final uses will include more than the stated equity value—but it explains why the contract can make funding Copart’s problem rather than ACV’s condition.

The asset being bought is a network for attaching services

Copart presents ACV as a route into whole cars and dealer-to-dealer wholesale remarketing. That is adjacent to, but not identical with, Copart’s historic centre of gravity. In fiscal 2025, insurance companies supplied 81% of the vehicles Copart processed. ACV’s marketplace instead connects licensed dealers and commercial sellers, supported by inspectors, pricing data, transport, floorplan finance, inventory software and buyer-assurance products.

The strategic wording matters because recent ACV growth did not come mainly from putting many more vehicles through the auction. In the June quarter, ACV reported 211,472 Marketplace Units, up only 0.5% from 210,429 a year earlier. Marketplace GMV was $2.7 billion in both periods. Auction marketplace revenue was almost unchanged at $92.4 million against $92.3 million.

Other marketplace revenue rose much faster, to $88.3 million from $75.4 million. ACV attributed the increase mainly to transport and financing, including higher transport revenue per mile as fuel costs were passed through. Customer-assurance revenue increased 39% to $24.7 million, while its related cost rose 28% to $21.7 million. The quarter produced $213.9 million of total revenue, an $8 million GAAP net loss and $20.8 million of adjusted EBITDA.

One quarter cannot establish a durable trajectory. Units can move with supply, used-car prices and dealer behaviour, while GMV is the value of vehicles transacted rather than ACV revenue. But the mix makes the control object visible. Copart is not merely purchasing an auction website. It is purchasing dealer relationships on which logistics, credit, assurance and data services can be attached.

The more products attached to the same transaction, the more integration becomes a question of rules as well as technology. Who controls seller onboarding, inspections, buyer eligibility, data access, pricing, transport allocation, financing limits and dispute remedies determines which services dealers see and what it costs them to transact. Those are also the surfaces on which promised revenue synergies could appear.

Copart’s own filing turned ACV into a competition fact

The antitrust issue is not an inference from both companies using the word “digital.” Copart’s 2025 Form 10-K explicitly listed ACV among the largest national or regional US vehicle auctioneers with which it competes, alongside RB Global’s Insurance Auto Auctions, Carvana, OPENLANE and Manheim. ACV’s own annual report names Manheim, ADESA and OPENLANE as principal large rivals and also describes smaller physical and digital competitors.

That evidence does not determine a legal market, market share or regulatory outcome. Salvage supply, whole-car dealer inventory, physical facilities, digital auctions, transport, financing and data may form different or overlapping competitive frames. The public record does not provide the customer-overlap or transaction-level substitution data needed to settle them.

It does explain why the merger agreement devotes real money and time to competition clearance. Hart-Scott-Rodino expiry or termination is an offer condition. So is the absence of a relevant injunction. If a competition authority objects, Copart must use reasonable best efforts to resolve the problem at least five business days before the End Date.

The listed toolkit is broad. It includes holding assets separate; selling, licensing or divesting businesses or property; terminating or changing investments and relationships; granting commercial accommodations; accepting limitations on how either group operates assets; and restructuring. The promise is framed through a reasonable-best-efforts standard, not as proof that Copart will accept every imaginable remedy. Still, the agreement deliberately places structural and behavioural concessions inside the buyer’s performance obligation.

Copart also controls and directs the approval strategy after consulting ACV and taking its views into account in good faith. That allocation is logical: the buyer decides what a combined portfolio is worth after a remedy. It also means the party paying the price controls the negotiation over which pieces it may have to give up.

The clock can outlast the calendar-year closing target

Management expects closing by the end of calendar 2026. The contract allows a much longer path.

The initial End Date is 11:59 p.m. New York time on the first anniversary of signing. If HSR clearance or a competition-law injunction is still outstanding then, while the representation, compliance and no-material-adverse-effect conditions have been satisfied, waived or remain capable of satisfaction as specified, the End Date automatically extends by 180 calendar days. A proceeding for specific performance can extend it further by the duration of the case plus five business days.

The distinction between forecast and legal capacity is important. A rapid HSR clearance could make management’s 2026 timetable possible. A second request, negotiated remedy or court action could move the transaction onto the longer contract clock. The existence of time does not mean it will be used; it means neither the year-end target nor the initial anniversary is the only valid scenario.

That waiting period has operating value and cost. ACV must continue running in the ordinary course under negotiated covenants while employees, dealers and competitors know a change of control is pending. Copart cannot yet exercise ownership, but it must prepare for an integration whose permitted perimeter could change. Dealers can reconsider where to send inventory or obtain finance. Rivals can recruit staff and court accounts. A regulatory delay is therefore not a neutral pause even when the buyer has ample cash.

Four per cent of support does not clear a majority gate

The offer provides a separate clock for shareholders. Copart must commence it within five business days if practicable and no later than seven business days after signing. It must remain open for at least ten business days. Merger Sub is not required to buy unless valid, unwithdrawn tenders—together with shares already owned by Copart and Merger Sub—represent one share more than 50% of ACV stock outstanding at expiry.

Supporting shareholders agreed to tender their shares promptly and, using reasonable best efforts, within five business days after commencement. Yet the support agreement covers only approximately 4.1% of the outstanding stock as of 8 September. It ends on specified events, including a materially adverse amendment, a lower offer price or a permitted change in ACV’s board recommendation.

The support stake is evidence of alignment, not completion. Roughly 95.9% of the register remains outside that disclosed commitment. Holders can tender for many reasons, and a 45% unaffected premium may be persuasive, but neither the premium nor unanimous board approval mechanically delivers the minimum condition.

Once the tender threshold and other conditions are satisfied and the shares are accepted and paid, the structure becomes faster. Delaware General Corporation Law Section 251(h) lets the back-end merger proceed without another shareholder vote. Remaining shares generally convert into the same cash consideration, subject to the stated exceptions and appraisal rights. The majority tender is therefore the decisive shareholder gate rather than a prelude to a second approval campaign.

The $115.3 million fee is a regulatory receipt, not insurance

If the agreement ends at the End Date while the HSR or competition-law injunction condition is unsatisfied and the other specified conditions are open, or if it ends because of a final competition-law restraint, Copart can owe ACV $115.3 million. ACV can owe Copart $57.7 million under different specified circumstances, including terminating to accept a superior proposal.

The buyer fee is exactly twice the seller fee. Relative to the announced $1.9 billion equity value, BTW calculates about 6.1% and 3.0%. That arithmetic shows materiality; it does not make the two promises mirror images. ACV’s fee principally protects the signed bargain against defined seller exits. Copart’s fee compensates ACV in a defined regulatory-failure corridor after the buyer has accepted the duty to pursue clearance.

The agreement describes each fee as a reasonable estimate of difficult-to-measure losses and, absent fraud, makes the applicable paid fee the exclusive remedy for that branch. That can cap recovery after a failed process even if employee attrition, customer uncertainty or forgone alternatives ultimately cost more. Conversely, ACV does not receive $115.3 million merely because review takes longer than hoped, and Copart does not earn a right to abandon the deal simply by budgeting for the fee.

The amount should therefore be monitored as a conditional receipt. First identify the termination section, then the state of the HSR, injunction, representation, compliance and no-MAE conditions, and only then ask whether the payment trigger exists. A regulatory headline alone is not enough.

Independence and synergy pull in opposite directions

Copart says ACV will operate as an independent subsidiary under its existing leadership. It also promises meaningful near-term cost and revenue synergies across dealer, commercial and retail channels. Both statements can be true, but they describe a governance tension that the filings do not resolve.

Keeping ACV operationally distinct may preserve its dealer brand, inspection force, product cadence and customer trust. Extracting revenue synergies may require shared leads, linked accounts, cross-sold services, pooled data or coordinated commercial policy. Cost synergies may involve overlapping vendors, facilities, technology or corporate functions. The companies disclose no dollar target, no integration cost and no timetable by product.

Management expects neutral EPS in the first full year of ownership and accretion in fiscal 2028 and beyond. That is a useful falsifiable sequence, not an earned result. It suggests that the first year must absorb the acquired earnings profile, purchase accounting and integration before promised growth overtakes the cost. ACV’s pre-deal 2026 guidance—$845 million to $855 million of revenue and $73 million to $77 million of adjusted EBITDA—provides a starting reference, but neither adjusted EBITDA nor revenue converts automatically into Copart EPS.

Funding certainty makes these operating questions more important, not less. Copart can write the cheque. The investment case depends on whether it can obtain permission for the intended perimeter, retain the dealer network through the waiting period and attach services without undermining the very competition and customer choice that regulators may examine.

Sources